Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Nan Chen"'
Autor:
Hanju Hua, Wenguang He, Nan Chen, Yinjun He, Guosheng Wu, Feng Ye, Xile Zhou, Yandong Li, Yongfeng Ding, Weixiang Zhong, Lisong Teng, Weiqin Jiang, Qinsong Sheng
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionTargetable alterations such as BRAFV600E mutation and NTRK fusion are enriched in microsatellite instability-high (MSI-H) colorectal cancer (CRC). MSI-H with targetable alterations (MSI-H altered) might present unique opportunities for bo
Externí odkaz:
https://doaj.org/article/67fb65324fc9412ba32e0e7a7b4fc2a3
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Antiviral immunity involves various mechanisms and responses, including the RNA interference (RNAi) pathway. During long-term coevolution, viruses have gained the ability to evade this defense by encoding viral suppressors of RNAi (VSRs). It was repo
Externí odkaz:
https://doaj.org/article/bc95d7d8a7614814b192caf502c3de46
Autor:
Yan Ouyang, Zhanzheng Zhao, Guisen Li, Huimin Luo, Feifei Xu, Leping Shao, Zijin Chen, Shuwen Yu, Yuanmeng Jin, Jing Xu, Manman Shi, Hafiz Muhammad Jafar Hussain, Wen Du, Zhengying Fang, Xiaoxia Pan, Weiming Wang, Jingyuan Xie, Nan Chen
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
We aimed to validate three IgAN risk models proposed by an international collaborative study and another CKD risk model generated by an extended CKD cohort with our multicenter Chinese IgAN cohort. Biopsy-proven IgAN patients with an eGFR ≥15 ml/mi
Externí odkaz:
https://doaj.org/article/30e93962d189424586f600a2a718e7e0
Autor:
Yan Ouyang, Li Zhu, Manman Shi, Shuwen Yu, Yuanmeng Jin, Zhaohui Wang, Jun Ma, Meng Yang, Xiaoyan Zhang, Xiaoxia Pan, Hong Ren, Weiming Wang, Hong Zhang, Jingyuan Xie, Nan Chen
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
The aim of this study was to investigate the association between lectin pathway-related genetic variations and progression in IgA nephropathy. Biopsy-proven IgAN patients with eGFR ≥15 ml/min/1.73 m2 at baseline and a minimum follow-up of 12-months
Externí odkaz:
https://doaj.org/article/b25cf756f8ea40b69e99abcea8c654db
Autor:
Huidi Zhang, Xixi Huang, Lulu Ye, Gangqiang Guo, Xiao Li, Chaosheng Chen, Li Sun, Baoqing Li, Nan Chen, Xiangyang Xue
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Our understanding of circulating microRNAs (miRNAs) related to systemic lupus erythematosus (SLE) remains very limited. In this study, we screened SLE-specific miRNAs in plasma from 42 B cell-related miRNAs by using miRNA PCR Array. The selected miRN
Externí odkaz:
https://doaj.org/article/c73d29691a9941b5b012936151d2c830
Autor:
Chi Zhang, Shuangshuang Feng, Wenting Zhang, Nan Chen, Abeer M. Hegazy, Wenjie Chen, Xueqin Liu, Lijuan Zhao, Jun Li, Li Lin, Jiagang Tu
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
BackgroundSnakehead vesiculovirus (SHVV), a new rhabdovirus isolated from diseased hybrid snakehead, has emerged as an important pathogen during the past few years in China with great economical losses in snakehead fish cultures. However, little is k
Externí odkaz:
https://doaj.org/article/c954fb33e915425bb8c978a34ad1de48
Autor:
Xue Yun Peng, Kai Lun Wang, Li Li, Bo Li, Xiang Yang Wu, Zhi Wei Zhang, Nan Li, Lan Hao Liu, Nie, P., Shan Nan Chen
Publikováno v:
Frontiers in Immunology; 2024, p1-13, 13p
The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
Publikováno v:
Frontiers in Immunology. 13
Immuno-checkpoint inhibitors (ICIs) bring a promising prospect for patients with cancers, which restrains the growth of tumor cells by enhancing anti-tumor activity. Nevertheless, not all patients benefit from the administration of ICIs monotherapy.
Autor:
Ming Zheng, Yi-Ming Li, Zhen-Yu Liu, Xin Zhang, Yinghui Zhou, Jian-Li Jiang, Ping Zhu, Xiang-Min Yang, Juan Tang, Zhi-Nan Chen
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Frontiers in Immunology
Frontiers in Immunology
Recently, immunotherapy targeting tumor-infiltrating lymphocytes (TILs) has emerged as a critical and promising treatment in several types of cancer. However, not all cancer types have been tested in immunotherapeutic trials, and different patients a
Autor:
Leping Shao, Manman Shi, Xiaoxia Pan, Zijin Chen, Hafiz Muhammad Jafar Hussain, Yan Ouyang, Feifei Xu, Nan Chen, Weiming Wang, Guisen Li, Wen Du, Zhengying Fang, Yuanmeng Jin, Jing Xu, Jingyuan Xie, Huimin Luo, Shuwen Yu, Zhanzheng Zhao
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
We aimed to validate three IgAN risk models proposed by an international collaborative study and another CKD risk model generated by an extended CKD cohort with our multicenter Chinese IgAN cohort. Biopsy-proven IgAN patients with an eGFR ≥15 ml/mi